Oncology News

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences in November 2026: UBS Global Biopharma Conference Date: November 17, 2026 Event Format: 1-on-1 meetings only Location: London, UK Jefferies Global Healthcare Conference in London Date: November 18 and 19, 2026 Fireside Chat: Wednesday, November 18, 2026 at 10:30AM GMT Event Format: Pre...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on October 13, 2026, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units (“RSUs”) representing 86,192 shares of its common stock to 118 new non-executive employees with a grant date of November 9, 2026, under the Guardant Health, Inc. 2023 Employment Inducement Incentive Award Plan (the “Inducement Plan”). The...

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) announced today that JAMA Network Open published the results of the prespecified secondary analysis of data from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy concomitant with gemcitabine and nab-paclitaxel in patients with unresectable, locally advanced pancreatic adenocarcinoma. The PANOVA-3 trial evaluated the use of TTFields therapy concomitantly with gemcitabine and nab-paclitaxel (GnP) as a first-line tre...

AUSTIN, Texas--(BUSINESS WIRE)--Two U.S. patents provide protection for PTM-101 in pancreatic cancer and support expansion of Sagittari™ platform across multiple tumor indications....

MENLO PARK, Calif.--(BUSINESS WIRE)--MedaSystems, a leading provider of secure, validated software for Expanded Access Programs (EAPs) and Post-Trial Access (PTA), today announced new research demonstrating how its AI technology can unlock valuable insights from real-world patient data.The research demonstrates how MedaSystems is extending the value of its platform beyond managing the complex workflows and compliance requirements of Expanded Access Programs to helping pharmaceutical companies an...

NEW HAVEN, Conn.--(BUSINESS WIRE)--On November 9–10, the inaugural Future of Oncology Summit brought together over 500 leaders from academia, biotechnology, pharmaceuticals, investment, and the broader oncology ecosystem at 101 College Street in New Haven. The two-day event featured more than 70 speakers, including keynote speakers Clifford Hudis, MD, CEO of the American Society of Clinical Oncology (ASCO), and Annie Lamont, co-founder and managing partner of Oak HC/FT, as well as remarks from...

BOSTON--(BUSINESS WIRE)--Ontada, a business dedicated to transforming community oncology through technology, announced new AI capabilities are available to iKnowMed customers....

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of WELIREG® (belzutifan), Merck’s first-in-class oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, plus lenvatinib, the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, for the treatment of adult p...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer, today announced the pricing of its underwritten public offering of 15,000,000 shares of its common stock at a price to the public of $10.00 per share. The gross proceeds to Vir Biotechnology from the offering are expected to be $150 million, be...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer, today announced that it intends to offer shares of its common stock in an underwritten public offering. In addition, Vir Biotechnology intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares...